San Francisco, 27 February 2024: The Report Facial Injectable Market Size, Share & Trends Analysis Report By Product (Collagen & PMMA Microspheres, Hyaluronic Acid), By Application (Facial Line Correction, Face Lift), By End-use, By Region, And Segment Forecasts, 2023 - 2030

The global facial injectable market size is expected to reach USD 24.92 billion by 2030, registering a CAGR of 12.0% from 2023 to 2030, according to a new report by Grand View Research, Inc.,The facial injectables are crucial in anti-aging treatments and are particularly used to stop damage such as hyperpigmentation and early aging. The most popular treatments across all socioeconomic groups are Botox and fillers, which have gained immense popularity.

Growing focus on physical appearance, especially in developing countries is one of the key factors expected to drive the market. In addition, a shift in consumer preference towards minimally invasive procedures is also expected to support market growth. According to the American Society of Plastic Surgeons (ASPS), in 2020, botulinum toxin A and soft tissue fillers were among the top 5 minimally invasive procedures carried out in the U.S. Thus, facial injectable holds high growth prospects in the years to come.

The onset of the pandemic led to nonurgent and cosmetic surgeries being put on hold in the first and second quarters of 2020. Since there were stringent restrictions imposed by the authority bodies as a precaution, the coronavirus outbreak has had an impact on every industry, including the cosmetics industry. Aesthetics-related product supply chains were also impacted. The demand-supply chain across the whole medical device sector has been severely disrupted by the pandemic.

A growing focus on physical appearance among consumers has led to an increased demand for facial injectables in recent years. The presence of a large population susceptible to various signs of aging has also boosted the demand for facial injectable medicine globally. Signs of aging, including wrinkles and sagging of the skin due to low facial elasticity, dark spots, and others, start appearing between 25 and 30 years of age and become more prominent from 30 to 65 years of age. Increasing awareness regarding minimally invasive procedures due to various beauty campaigns being organized by key players in the market is also a driving factor for market growth.

Minimally invasive surgeries are rapidly replacing invasive surgeries. For instance, according to the American Society of Plastic Surgeons (ASPS), in the U.S., nearly 18 million minimally invasive and surgical cosmetic products were performed in 2020, out of which nearly 16 million products were minimally invasive. Thus, the increasing adoption of minimally invasive surgeries, coupled with the availability of a wide range of such treatment options, is driving market growth.

Request sample report of Facial Injectable Market@ https://www.grandviewresearch.com/industry-analysis/facial-injectables-industry/request/rs1

The presence of well-established key players such as Allergan, Sinclair Pharma, and Galderma with a comprehensive injectable fillers portfolio treating a broad range of skin indications such as wrinkles, pigmentation, plumping of lips, scars, restoring facial fullness as well as enhancing facial contours is expected to drive the demand for facial injectable procedures thereby boosting market revenue. Increasing social media exposure, rising effectiveness, and approvals for facial injectables as well as the escalating desire among the population to look aesthetically appealing and young is expected to drive the market during the forecast period.

Facial Injectable Market Report Highlights

• Based on product, the botulinum toxin type A segment is projected to dominate the market throughout the forecast period. It is one of the most popularly used minimally invasive procedures
• Based on application, the facial line correction segment dominated the market and accounted for the largest revenue share of 33.2% in 2022. This growth is owing to the increasing use of facial injectables for aesthetic procedures such as facial lines, wrinkles on the face, and lip lines
• Based on end-use, the medSpa segment dominated the market and held the largest revenue share of 46.8% in 2022. All noninvasive treatments are performed in these facilities, which include facial injections, non-invasive body contouring, skin rejuvenation, and laser treatments by experienced professionals
• North America dominated the market with a revenue share of 39.7% in 2022 owing to the easy availability of the products and the presence of a large number of skilled surgeons
• The Asia Pacific region is expected to serve as a key revenue-generating center. The region is backed by countries such as India, where a growing focus on physical appearance is expected to create a lucrative opportunity for the market

According to the International Society of Aesthetic Plastic Surgery (ISAPS), the U.S. was ranked 1^st in terms of non-surgical products performed at a global level. Of these, injectables such as botulinum toxin and hyaluronic acid were among the most popular products performed. The country is backed by advanced treatment options and has the highest number of surgeons globally, with over 7,000 plastic surgeons as of 2023. These factors support market growth.

In June 2020, Allergan Aesthetics, a subsidiary of AbbVie Inc. (U.S.), received FDA approval for JUVÉDERM VOLUMA XC for the augmentation of the chin region in adults over the age of 21. Apart from this, in 2023, the FDA approved, Jeuveau which is similar to Botox, but available at a lower cost compared to Botox. The product is found to be effective in reducing wrinkles.

The aesthetic industry witnessed a significant setback due to the COVID-19 pandemic in the initial quarters of 2020. There was a drop in the revenue of the manufacturers due to supply chain disruptions. However, the survey conducted by Cynosure in June 2020 reported that the majority of the surveyed population showed a high willingness to opt for in-office non-invasive treatments. Even during the pandemic Botox and soft tissue fillers remained the most popular minimally invasive procedures in the U.S.

Facial Injectable Market Report Scope

Based on product, the botulinum toxin segment dominated the marketand accounted for the largest revenue share of 53.0% in 2022. Middle-aged women are increasingly opting for fillers and injectables including the popular, Botox to reverse the signs of aging. The Hyaluronic Acid (HA) segment is projected to witness the fastest CAGR of 12.3% during the forecast period. It is known for its ability to store moisture in the skin, thus making the skin look healthier. HA has a moisture-binding characteristic that helps enhance and maintain the vital moisture responsible for the plumpness of the facial skin.

The cosmetic-grade HA has a low molecular weight that facilitates deep penetration of the product in the epidermis, which further helps retain water in the cells and releases antioxidants that delay the aging process. According to the International Society of Aesthetic, around 4,053,016 procedures for hyaluronic dermal injections were performed globally in 2020.

List of Key Players in the Facial Injectable Market

• Ispen
• Abbvie
• Medytox Inc.
• Merz GmbH and Co. KGaA
• Revance Therapeutics, Inc.
• Galderma
• Sinclair Pharma